Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Guardant Health Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Guardant Health Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Guardant Health Inc
NASDAQ:GH
PP&E Net
$270.1m
CAGR 3-Years
-4%
CAGR 5-Years
46%
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
PP&E Net
$5.4B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
9%
Quest Diagnostics Inc
NYSE:DGX
PP&E Net
$2.8B
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
12%
CVS Health Corp
NYSE:CVS
PP&E Net
$29B
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
13%
Cigna Corp
NYSE:CI
PP&E Net
$3.6B
CAGR 3-Years
-8%
CAGR 5-Years
-6%
CAGR 10-Years
9%
Laboratory Corporation of America Holdings
NYSE:LH
PP&E Net
$3.1B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
15%
No Stocks Found

Guardant Health Inc
Glance View

Market Cap
4.3B USD
Industry
Health Care

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

GH Intrinsic Value
34.89 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Guardant Health Inc's PP&E Net?
PP&E Net
270.1m USD

Based on the financial report for Sep 30, 2024, Guardant Health Inc's PP&E Net amounts to 270.1m USD.

What is Guardant Health Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
46%

Over the last year, the PP&E Net growth was -13%. The average annual PP&E Net growth rates for Guardant Health Inc have been -4% over the past three years , 46% over the past five years .

Back to Top